⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIOA News
BioAge Labs, Inc. Common Stock
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
prnewswire.com
BIOA
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
globenewswire.com
BIOA
Form 8-K
sec.gov
BIOA
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
prnewswire.com
BIOA
Bulletin from the Annual General Meeting in BioArctic AB (publ) USA - English USA - English
prnewswire.com
BIOA
BioAge Labs to Present at Upcoming Investor Conferences
globenewswire.com
BIOA
BTAI
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
prnewswire.com
LCTX
FATE
GERN
BIOA
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach
prnewswire.com
BIOA
CRSP
VRTX
VYGR
Form 8-K
sec.gov
BIOA
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
BIOA